$50 Million

Ovid Therapeutics

Follow-on Offering

Lead Left Bookrunner, August 2020

Ovid Therapeutics Inc. is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Company’s most clinically-advanced product candidate, OV101, is a first-in-class δ-selective GABAA receptor agonist. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company for the potential treatment of rare developmental and epileptic encephalopathies (DEE). ovi

More Like This

Sep 2020
$86 Million

Follow-on Offering

Bookrunner

View Details
Sep 2020
$80 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Sep 2020
$150 Million

Follow-on Offering

Lead Left Bookrunner

View Details